Pharma 2020: From vision to decision
The pharmaceutical industry is at a critical juncture. The tools to develop remarkable new medicines are materializing, demand for its products is increasing and the barriers to free trade are falling. But pharma also faces major economic and operational challenges, if it’s to capitalize these opportunities and create more value for healthcare payers, providers and patients.
Many of the conditions that will determine what happens in 2020 are already in place. Most of the products that will be launched are already in the pipeline; the processes being used to develop them are similar to those used for the past 10 years; the prevailing management culture remains that of the late 20th century; and a demanding commercial environment looks set to continue.
But that doesn't mean pharma's fate is sealed. We’ve outlined our vision of the future in previous Pharma 2020 publications. We’ll focus here on how companies can reach 2020 in a position to benefit from more favourable conditions thereafter — and the most important decisions senior management will need to make. To download the full report, click here.
Operating performance in the medtech industry: Trends and imperatives
With an era of high growth and profitability in the Medtech industry having given way to slower growth and flat profits, operating performance is becoming a critical driver of shareholder value for Medtech companies. This brief analyzes trends in operating performance for the industry and its various segments, and explains how Medtech companies can identify which levers to pull to improve their operating performance. To download the full brief, click here.
Moving towards good practice in the reimbursement of CIED Telemonitoring
The possibility to monitor patients and their cardiac implants such as pacemakers or defibrillators remotely has the potential to improve the efficiency of Cardiac Implant Electronic Device (CIED) therapy, and make the treatment more cost-effective. Nonetheless, to date, remote monitoring of patients is still not used widely throughout Europe. Findings from the research “Moving towards good practice in the reimbursement of CIED Telemonitoring”, published by PwC in cooperation with Eucomed and EHRA, the European Heart Rhythm Association, concluded that appropriate reimbursement systems are critical in fostering uptake of such innovative telemonitoring solutions. Click here to download the full paper from Eucomed.
CBI’s 3nd Annual West Coast Life Sciences Compliance Congress
November 28-29, 2012, San Francisco, CA
The West Coast Life Sciences Compliance Congress is a meeting place for CCOs and their teams to network, share compliance best practices and discuss all aspects of strategic compliance program management. Attendees will gain insights directly from regulators and prosecutors, analyze FDA Guidances, examine CIA and FCPA settlements and receive an update on the final Sunshine requirements and interpretation of other legislation and regulations impacting life science compliance teams. PwC is a sponsor of this congress. Peter Claude will be moderating a panel and Oscar Perdomo will be speaking. To learn more about this upcoming event, click here.